OssDsign announces that SEB has initiated research coverage of the company
Uppsala, June 8, 2022. OssDsign AB (publ.) today announces that Skandinaviska Enskilda Banken (publ) (SEB) has been engaged to produce regular corporate research reports on the company. The intention is to raise the visibility of OssDsign in the capital market and enable investors as well as other stakeholders to develop an improved understanding of its business.
"We are glad to announce that SEB, one of the most well-renowned financial institutions in the Nordics, has initiated corporate research coverage in OssDsign. This will further increase our visibility in the financial community," comments Morten Henneveld, CEO, OssDsign.
Please visit https://research.sebgroup.com/corporate/reports/114951 to read SEB:s initiation of coverage report in OssDsign.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: